

Review of: "TROPION-Lung01 Results Indicate PFS Benefit with Datopotamab Deruxtecan over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and Question"

Chong Kin Liam¹

¹ University of Malaya

Potential competing interests: No potential competing interests to declare.

The study shows that there is a significant and clinically meaningful improvement in PFS in patients with previously treated advanced/metastatic non–small cell lung cancer (NSCLC) treated with datopotamab deruxtecan (Dato-DXd) compared to docetaxel. This improvement in PFS is driven by patients with non-squamous NSCLC. However, the OS was not significantly improved. Compared to docetaxel, Dato-DXd should not be the treatment option for patients with previously treated squamous NSCLC because of the lack of efficacy in terms of PFS.